Drug
Brivaracetam
Brivaracetam: highest development phase Phase 3, developed by UCB. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brivaracetam NCT04666610 | Phase 3 | Childhood Absence Epilepsy |
| Brivaracetam NCT00504881 | Phase 3 | Epilepsy |
| Brivaracetam (BRV) NCT01364597 | Phase 3 | Epilepsy |
| Brivaracetam 25 mg NCT00357669 | Phase 3 | Unverricht-Lundborg Disease |
| Brivaracetam NCT03021018 | Phase 2 | Epilepsy |
Latest
No recent events.
Follow Brivaracetam on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.